Mounjaro: Superior A1C reduction. Unmatched weight results.1
Mounjaro is not indicated for weightloss
Change in weight was a secondary endpoint
Limitations of Use
Mounjaro has not been studied in patients with a history of pancreatitis. Mounjaro is not indicated for use in patients with type 1 diabetes mellitus.
Mounjaro is the first in a new class for the treatment of T2D1
The first and only GIP and GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes. ||| h4
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; T2D=type 2 diabetes.
Mounjaro works differently1
A single molecule that activates the GIP and GLP-1 receptors in the body.1
Select Important Safety Information
Hypoglycemia with concomitant use of insulin secretagogues or insulin: Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Superior A1C reduction across clinical trials1*
* Across the five phase 3 SURPASS studies, mean reductions in A1C with Mounjaro ranged from 1.8% to 2.1% for the 5-mg dose, 1.7% to 2.4% for the 10-mg dose, and 1.7% to 2.4% for the 15-mg dose; and for comparators, 0.1% and 0.9% for placebo, 1.9% for Ozempic® 1 mg, 1.3% for Tresiba®, and 1.4% for insulin glargine. p<0.05 for superiority vs. study comparators, adjusted for multiplicity.1
Unmatched weight results across clinical trials1†
Mounjaro is not indicated for weight loss. Change in weight was a secondary endpoint.
† Across the five phase 3 SURPASS studies, mean reductions in body weight ranged from 12 lb to 17 lb for the 5-mg dose, 15 lb to 21 lb for the 10-mg dose, and 17 lb to 25 lb for the 15-mg dose; and for comparators, mean change was -2 lb and +4 lb for placebo, +4 lb for Tresiba®, +4 lb for insulin glargine, and -13 lb for Ozempic® 1 mg. p<0.05 for superiority of Mounjaro vs study comparators, adjusted for multiplicity.1
Select Important Safety Information
WARNING: RISK OF THYROID C-CELL TUMORS ||| h5
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.
Reference:
- Mounjaro. Prescribing Information. Lilly USA, LLC.
HCP and Patient Testimonials
Hear from adult patients with type 2 diabetes and health care providers on why Mounjaro was an appropriate choice of therapy.
Coming soon